Abstract
Cerebral cavernous malformation (CCM) is a cerebrovascular disorder of proven genetic origin characterized by abnormally dilated and leaky capillaries occurring mainly in the central nervous system, with a prevalence of 0.3–0.5% in the general population. Genetic studies have identified three genes associated to CCMs: KRIT1 (CCM1), MGC4607 (CCM2), and PDCD10 (CCM3), which account for about 50%, 20%, and 10% of the cases, respectively. The great advances in the knowledge of the physiopathological functions of CCM genes, such as their involvement in the angiogenic process, have allowed to propose distinct putative therapeutic compounds, which showed to be effective at least in limiting some pathological phenotypes in cellular and animal models of the disease. However, despite numerous efforts, targeted pharmacological therapies that improve the outcome of CCM disease are currently lacking.
Here we describe simply and low-cost assays as in vitro endothelial cell proliferation and migration assays that can be used to better understand the role of CCM genes on endothelial cell functions and to screen potential new compounds for CCM therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gault J, Sarin H, Awadallah NA et al (2004) Pathobiology of human cerebrovascular malformations: basic mechanisms and clinical relevance. Neurosurgery 55(1):1–16
Glading A, Han J, Stockton RA et al (2007) KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell cell junctions. J Cell Biol 179(2):247–254
Glading AJ, Ginsberg MH (2010) Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling. Dis Model Mech 3(1–2):73–83
Stockton RA, Shenkar R, Awad IA et al (2010) Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med 207(4):881–896
Corr M, Lerman I, Keubel JM et al (2012) Decreased Krev interaction-trapped 1 expression leads to increased vascular permeability and modifies inflammatory responses in vivo. Arterioscler Thromb Vasc Biol 32(11):2702–2710
DiStefano PV, Kuebel JM, Sarelius IH et al (2014) KRIT1 protein depletion modifies endothelial cell behavior via increased vascular endothelial growth factor (VEGF) signaling. J Biol Chem 289(47):33054–33065
You C, Sandalcioglu IE, Dammann P et al (2013) Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations. J Cell Mol Med 17(3):407–418
Wüstehube J, Bartol A, Liebler SS et al (2010) Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc Natl Acad Sci U S A 107(28):12640–12645
Zhu Y, Wu Q, Xu JF et al (2010) Differential angiogenesis function of CCM2 and CCM3 in cerebral cavernous malformations. Neurosurg Focus 29(3):E1
Jung KH, Chu K, Jeong SW et al (2003) Cerebral cavernous malformations with dynamic and progressive course: correlation study with vascular endothelial growth factor. Arch Neurol 60(11):1613–1618
Abe T, Morishige M, Ooba H et al (2009) The association between high VEGF levels and multiple probable punctuate cavernous malformations. Acta Neurochir 151(7):855–859
Park SJ, Park SH (2016) Systemic expression of vascular endothelial growth factor in patients with cerebral cavernous malformation treated by stereotactic radiosurgery. J Korean Neurosurg Soc 59(5):442–448
Girard R, Zeineddine HA, Fam MD et al (2018) Plasma biomarkers of inflammation reflect seizures and hemorrhagic activity of cerebral cavernous malformations. Transl Stroke Res 9(1):34–43
Fallah A, Sadeghinia A, Kahroba H et al (2019) Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. Biomed Pharmacother 110:775–785
Louvi A, Chen L, Two AM et al (2011) Loss of cerebral cavernous malformation 3 (Ccm3) in neuroglia leads to CCM and vascular pathology. Proc Natl Acad Sci U S A 108(9):3737–3742
Nowak-Sliwinska P, Alitalo K, Allen E et al (2018) Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 21(3):425–532
Finetti F, Terzuoli E, Donnini S et al (2016) Monitoring endothelial and tissue responses to cobalt ferrite nanoparticles and hybrid hydrogels. PLoS One 11(12):e0168727
De Rosa L, Finetti F, Diana D et al (2016) Miniaturizing VEGF: peptides mimicking the discontinuous VEGF receptor-binding site modulate the angiogenic response. Sci Rep 6:31295
Stryker ZI, Rajabi M, Davis PJ et al (2019) Evaluation of angiogenesis assays. Biomedicines 7(2). pii: E37
Finetti F, Basile A, Capasso D et al (2012) Functional and pharmacological characterization of a VEGF mimetic peptide on reparative angiogenesis. Biochem Pharmacol 84(3):303–311
Boyden S (1962) The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 115:453–466
Finetti F, Solito R, Morbidelli L et al (2008) Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem 283(4):2139–2146
Acknowledgments
This work was supported by the Telethon Foundation (grant GGP15219) to LT and MIUR (Progetto Dipartimento di Eccellenza 2018–2022) to LT and FF.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Finetti, F., Trabalzini, L. (2020). Bidimentional In Vitro Angiogenic Assays to Study CCM Pathogenesis: Endothelial Cell Proliferation and Migration. In: Trabalzini, L., Finetti, F., Retta, S. (eds) Cerebral Cavernous Malformations (CCM) . Methods in Molecular Biology, vol 2152. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0640-7_27
Download citation
DOI: https://doi.org/10.1007/978-1-0716-0640-7_27
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-0639-1
Online ISBN: 978-1-0716-0640-7
eBook Packages: Springer Protocols